Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment (IMPACT)

June 25, 2025 updated by: Boston Medical Center

This study will identify unique signatures that people have which can cause pain by evaluating biological, psychological, and social markers using artificial intelligence. These markers can be used to accurately predict the response of diverse individuals with chronic low back pain (cLBP) to Mindfulness-Based Stress Reduction. This will help enhance clinician decision-making and the targeted treatment of chronic pain.

The overall objective is to use a unique machine learning (ML) approach to determine the biomarker signature of persons undergoing mindfulness based stress reduction (MBSR) treatment for their chronic low back pain (cLBP). This signature will facilitate clinical prediction and monitoring of patient response to MBSR treatment.

The design of the study is a single-arm clinical trial of the evidence-based MBSR program for patients with cLBP.

Study Overview

Detailed Description

UG3 Phase Overview. The first 24-months of the project will be dedicated to performing machine learning modeling to identify candidate predictive and monitoring markers of cLBP response to MBSR, prior to the full clinical trial in the UH3 phase. We will also refine our procedures such as recruitment and outcomes assessment with 50 persons during the UG3 phase.

UH3 Phase Overview. Biopsychosocial markers will be identified of the response of diverse cLBP patients to MBSR (N=300) from comprehensive pain assessment and biopsychosocial data, including pain intensity and pain interference, physical activity, sleep, and heart rate for a 6-month period. Data will be collected and used for training and testing ML models. The MBSR program is evidence-based and meets weekly in a group via Zoom for 8-weeks for 90 minutes per week. Measures to determine biomarkers will be obtained at baseline (T1), four-weeks (T2), program completion (T3), four months (T4), and six months (T5). The main outcome timepoint with be at six months (T5), which allows time for durability of effects to be determined. The PEG (Pain, Enjoyment, General activity), obtained through online self-report surveys is the main outcome measure. Secondary outcomes of physical and psychological function will be self-report and obtained online, or if the patient prefers, by telephone, and physical activity, sleep, and heart rate variability will be collected by Fitbit.

Study Type

Interventional

Enrollment (Estimated)

350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02116
        • Recruiting
        • Boston Medical Center
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Chronic low back pain, which is pain that persists for at least 3-months and has resulted in pain on at least half the days in the past 6 months
  • Willing and able to provide online or telephone informed consent
  • Speak English as the intervention manual is currently written in English

Exclusion Criteria:

  • Red flags- recent (past month) worsening of pain, unexplained fever, unexplained weight loss
  • Pregnancy
  • Metastatic cancer
  • Not a patient at a participating clinic or persons not planning to continue as a patient at a participating clinic for 6 or more months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness based stress reduction (MBSR) program
Participants will be enrolled in a 8-week mindfulness clinical pain program + Primary Care Provider (PCP) Usual Care.
Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain, Enjoyment, General activity (PEG) composite score
Time Frame: 6 months
The PEG is a 3-question scale: "pain average", "interference with general activity" and "interference with enjoyment of life". Each question is on a 0-10 scale, and total PEG is the average. Scores can range from 0-30 and <12=Mild,12 to <21 = Moderate, 21 to 30 = Severe chronic pain.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression assessed by the eight-item Patient Health Questionnaire for Depression (PHQ-8)
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The total score is determined by adding together the scores of each of the four items. Scores are rated as normal (0-2), mild (3-5), moderate (6-8), and severe (9-12). Total score ≥3 for first 2 questions suggests anxiety. Total score ≥3 for last 2 questions suggests depression.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Anxiety assessed by the Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Pain Self-Efficacy assessed by the Pain Self-Efficacy Questionnaire
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PSEQ is a 10-question survey that measures the confidence of a person with persistent pain to do a range of activities while in pain. The total score ranges from 0 to 60. High PSEQ scores are strongly associated with clinically- significant functional levels and provide a useful gauge for evaluating outcomes in chronic pain patients. Higher scores (and a higher percentile) represent higher confidence to function with pain.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Catastrophizing assessed by the Pain Catastrophizing Scale Short Form
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The Pain Catastrophizing Scale (PCS) measures three aspects of catastrophic cognitions about pain-rumination, magnification, and helplessness. It consists of 13 items scored from 0 to 4, with a total range of 0 to 52. Higher scores are less favorable and a score of more than 30 points may indicate clinical relevance.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Quality of Life assessed by the Patient Reported Outcomes Measurement Information System (PROMIS 29)
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PROMIS-29 v2. 0 profile measure assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items for each domain. HIgher scores indicate greater pain intensity.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Participants' Impression of change
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
Patient Global Impression of Change (PGIC) will be used to assess this outcome. A score of 1=No change (or condition has got worse), 2 = Almost the same, hardly any change at all, 3 = A little better, but no noticeable change, 4 = Somewhat better, but the change has not made any real difference, 5 = Moderately better, and a slight but noticeable change, 6 = Better, and a definite improvement that has made a real and worthwhile difference 7 = A great deal better, and a considerable improvement that has made all the difference. A 2-point change is significant from the last reported score
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Mindfulness assessed by the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The CAMS-R is a 12-item measure designed to capture a broad conceptualization of mindfulness with language that is not specific to any particular type of meditation training. Items 2, 6, and 7 are reverse-scored. After appropriate reversals, values for items 1 - 12 are summed. Higher values reflect greater mindful qualities.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Sleep disturbance assessed by the PROMIS Sleep Disturbance-Short Form 6a
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PROMIS 6a scale is composed of 6 items developed to assess the domain of sleep disturbances in the past 7 days. The first two scale items assess sleep quality and the following 4 items assess domains of restfulness, sleep problems, and difficulty falling asleep. Each question has five response options ranging in value from one to five. To find the total raw score for a short so the range of scores is 6 to 30.
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Pain-Sleep Duration
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
One question assesses sleep duration. This survey measures the impact of pain on the quality of sleep
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Treatment components and effects assessed by the Healing Encounters and Attitudes List-Expectation
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
Six questions ask about treatment expectancy. It assesses participants' attitudes towards and perceptions of treatment components that associated with nont specific treatment effects
baseline, 4 weeks, 8 weeks, 4 months, 6 months
Social support assessed by the Social Network Index
Time Frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
12 questions that ask about social support in regards to how many people a person sees and talk to regularly. The total score is calculated by finding the sum of the all items with a higher score indicating more social engagement.
baseline, 4 weeks, 8 weeks, 4 months, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Natalia Morone, MD MS, Boston Medical Center
  • Principal Investigator: Jean King, PhD, Worcester Polytechnic Institute
  • Principal Investigator: Emmanuel Agu, PhD, Worcester Polytechnic Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 25, 2024

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

October 24, 2023

First Submitted That Met QC Criteria

October 24, 2023

First Posted (Actual)

October 30, 2023

Study Record Updates

Last Update Posted (Actual)

June 26, 2025

Last Update Submitted That Met QC Criteria

June 25, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Low-back Pain

Clinical Trials on Mindfulness meditation

Subscribe